A Chinese drug against "Covid-19" succeeded in obtaining approval to enter the markets of eight countries, the last of which was Singapore.
On Friday, Xinhua quoted Yiling Pharmaceutical Company - based in Shijiazhuang City, Hebei Province in north China - as saying that the "Lianhua Chengon" capsule was officially listed as a Chinese drug by the Health Sciences Authority of Singapore, which means giving the drug the right to enter the market Singaporean.
The agency added that the clinical observation of Covid-19 therapy in designated Chinese hospitals showed that traditional Chinese medicines, including the "Lianhua Chengon" capsule, were effective in treating more than 90% of confirmed Covid-19 cases on the Chinese mainland.
For his part, said the famous Chinese expert in the respiratory system, Zhong Nanshan, that the laboratory experiment demonstrated that the capsule of "Lianhua Qingon" has a weak inhibitor effect on the virus, but it is characterized by good treatment effectiveness of the affected cells and inflammation caused by the emerging corona virus.
While the general manager of Yiling Pharmaceutical Company, Wu Xiangjun, pointed out that the "Lianhua Chengon" capsule obtained market approval from drug departments in eight countries including Brazil, Romania, Thailand, Ecuador and Singapore. The company donated quantities of medicine to Iraq, Italy and other countries to help in its efforts to combat the epidemic.